Buffalo, NYNCT05874414Now EnrollingIRB Ready

Bile Duct Cancer Clinical Trial in Buffalo, NY

Access cutting-edge bile duct cancer treatment through this phase 1/2 clinical trial at a research site in Buffalo. Study-provided care at no cost to qualified participants.

Sponsored by Genfit

Quick Self-Assessment

See if you qualify for this Buffalo location

Preparing your pre-screening questions…

Expert Care in Buffalo

Access bile duct cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related bile duct cancer treatment provided free

Apply for This Buffalo Location

Check if you qualify for this bile duct cancer clinical trial in Buffalo, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Buffalo

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Buffalo site if eligible
  4. 4Begin participation

About This Bile Duct Cancer Study in Buffalo

This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

Sponsor: Genfit

Who Can Participate

Inclusion Criteria

Histologically confirmed intrahepatic CCA with a documented KRAS mutation.
Patients greater than or equal to 18 years of age.
Patients must have disease progression that is not amenable to potentially curative treatment.
Patients must have received one or two lines of chemotherapy.
Patients must have at least one measurable disease by RECIST v1.1.
Performance status (ECOG) 0-1.
Adequate organ baseline function defined as follows: absolute neutrophil count ≥1000 cells/μL, platelet count ≥75,000 cells/μL, hemoglobin ≥9 g/dL, aspartate aminotransferase or alanine aminotransferase less than or equal to 3 × upper limit of normal, estimated glomerular filtration rate ≥60 mL/min, corrected QT interval by Fridericia's (QTcF) interval ≤470 msec.
Women of childbearing potential must present with a negative serum pregnancy test and agree to use adequate contraception during the study and until 6 months after the end of treatment. Male patients with women partners of childbearing potential must agree with the contraception procedures of the study protocol.
Patients must be able to understand and be willing to comply with the requirements of the study protocol.
Patients participate voluntarily and sign informed consent form(s).

Exclusion Criteria

Previous treatment with a MEK inhibitor or autophagy inhibitor.
Previous treatment with three or more lines of prior chemotherapy.
Extrahepatic CCA with recent (within 6 weeks) placement of a stent or episodes of unstable biliary stents (manifest as obstruction, migration of the stent, infevtion or mechanical failure of the stent) within 6 weeks according to investigator's judgement.
Current evidence of uncontrolled, significant intercurrent illness including, but not limited to, the following conditions:
Cardiovascular disorders: congestive heart failure New York Heart Association ≥ class 2 or left ventricular ejection fraction (LVEF) \<50%, arrythmias or cardiac conduction abnormalities. Uncontrolled arterial hypertension or inadequately controlled arterial hypertension, at the discretion of the investigator, based on an average of = \>3 BP readings over = \>2 sessions.
Patients who have retinal condition (retinal tear, exudate, hemorrhage) or history of retinal vein occlusion or central serous retinopathy or retinal pigment epithelial detachment.
History of interstitial lung disease or pneumonitis.
Patients who have clinically significant pleural effusion or ascites.
Patients who have neurological condition (e.g., tremor, ataxia, hypotension, confusion), history of seizures or active central nervous system metastases.
Impairment of gastrointestinal function or gastrointestinal disease (e.g., diarrhea, active ulcer disease, history of gastrointestinal perforation/hemorrhage, malabsorption or other conditions that under the judgment of the principal investigator (PI) may impair absorption of study drugs).
Patients who are taking antineoplastic drugs for concomitant cancer or history of malignancy other than CCA within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate \> 90%) such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
Any other condition that would, in the Investigator s judgment, contraindicate the patients' participation in the clinical study due to safety concerns or compliance with clinical study procedures (e.g., infection, unable to swallow medication, social/psychological issues, etc).
Known active viral hepatitis, including HBV and HCV.
Patients with known allergic reaction to quinoline derivatives (e.g., quinine, chloroquine, mefloquine) and/or hypersensitivity to study drugs.
Patients who have not recovered for certain AEs due to previous lines of therpay.
Female patients who are pregnant or lactating at the time of enrollment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Buffalo?

Yes, this clinical trial (NCT05874414) has an active research site in Buffalo, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Bile Duct Cancer Treatment Options in Buffalo, NY

If you're searching for bile duct cancer treatment options in Buffalo, NY, this clinical trial (NCT05874414) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Buffalo research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced bile duct cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all bile duct cancer clinical trials near you to find additional studies recruiting in your area.

More Gallbladder Cancer Trials in Buffalo, NY

See all gallbladder cancer clinical trials recruiting in Buffalo — not just this study.

Browse Gallbladder Cancer Trials in Buffalo →

Browse More Trials by Condition

Gallbladder Cancer TrialsUlcerative Colitis TrialsAll Conditions →

Ready to Join in Buffalo?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Buffalo, NY